2Seventy Bio Inc
NASDAQ:TSVT
2Seventy Bio Inc
Stock-Based Compensation
2Seventy Bio Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
2Seventy Bio Inc
NASDAQ:TSVT
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$911m
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$835m
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$530m
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$698.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
$982.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
2Seventy Bio Inc
Glance View
2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.
You don't have any saved screeners yet